Our results show that CLU is commonly downregulated in lung cancer and its downregulation correlates with poor patient survival and disease progression, indicating that CLU downregulation significantly contributes to lung cancer development and progression and might represent an early diagnostic marker for metastatic lung cancer patients. Here, CLU is linked to lung cancer.